https://m2.mtmt.hu/ hun 2026-07-28 04:52 JournalArticle 35061032 VALIDATED true 0 false 2026-05-23T23:05:33.917+0000 2025-01-05T21:11:36.835+0000 2024-06-20T13:28:18.316+0000 true 10067747 Reményiné Kállai Zsuzsa /api/admin/10067747 Admin Reményiné Kállai Zsuzsa (DE admin 4) true 2026-03-09T10:31:01.396+0000 2024-09-19T11:04:31.359+0000 true 521 Szuper Admin /api/admin/521 Admin Szuper Admin (admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Mark, Laszlo true true /api/journal/10017543 REVIEWED JOURNAL OF CLINICAL MEDICINE 2077-0383 true false 10017543 false 10017543 true 2077-0383 Journal FOREIGN 13 12 3398 3398 2024 Background/Objectives: Patients with acute coronary syndrome (ACS) represent a vulnerable population. We aimed to investigate serum lipid levels of patients with ACS upon admission and during one year of the COVID-19 pandemic in a rural county hospital, and compared these findings with the data of patients with ACS in 2015 and 2017. The secondary aim of this paper was the comparison of the LDL-C values calculated with the Friedewald and Martin–Hopkins methods. Methods: A retrospective analysis of lipid-lowering data of patients treated with ACS in 2015, 2017 and in a COVID-19 year (1 April 2020–31 March 2021) was performed; the patient’s numbers were 454, 513 and 531, respectively. Results: In the COVID-19 period one year after the index event, only 42% of the patients had lipid values available, while these ratios were 54% and 73% in 2017 and in 2015, respectively. Using the Friedewald formula, in the COVID-19 era the median of LDL cholesterol (LDL-F) was 1.64 (1.09–2.30) mmol/L at six months and 1.60 (1.19–2.27) mmol/L at one year, respectively. These values were 1.92 (1.33–2.27) mmol/L and 1.73 (1.36–2.43) mmol/L using the Martin–Hopkins method (LDL-MH). The LDL-F yielded significantly lower values (15% lower at six months, p = 0.044; and 8% lower at one year, p = 0.014). The LDL-F reached the previous target of 1.8 mmol/L during the COVID-19 pandemic 36% at one year vs. 48% in 2017, and 37% in 2015. The recent target LDL-C level of 1.4 mmol/L was achieved in 22% of cases in the COVID-19 pandemic, 16% in 2015 and 19% in 2017. Conclusions: A significantly lower proportion of patients with ACS had available lipid tests during the COVID-19 pandemic. Besides the lower number of available samples, the proportion of achieved 1.4 mmol/L LDL-C target lipids was stable. More rigorous outpatient care in the follow-up period may help to improve the quality of lipid lowering treatments and subsequent secondary cardiovascular prevention. If direct LDL-C determination is not available, we prefer the LDL calculation with the Martin–Hopkins method. true 2024 true true true false true false GOLD 2026-05-24 false http://www.mdpi.com/journal/jcm 2 0 2 0 2 1 2 2 2 2 2 0 0 0 2 0 2 0 2 0 0 13 13 Folyóiratcikk Journal Article 24 2 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 2 0 2 0 Q1 false 10038794 false false false 2024-09-18T13:28:27.998+0000 Anyagcsere Betegségek Nem Önálló Tanszék (DE / ÁOK / BelgyI) 4 10 1 7 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 117986501 /api/authorship/117986501 Mark, Laszlo [Márk, László (Belgyógyászat, ka...), szerző] 1 0.14285715 true false false Author 10047613 /api/author/10047613 Márk László (Belgyógyászat, kardiológia) Márk László true 10047613 true Mark Laszlo true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 117986502 /api/authorship/117986502 Fülöp, Péter [Fülöp, Péter (Belgyógyászat, en...), szerző] Anyagcsere Betegségek Nem Önálló Tanszék (DE / ÁOK / BelgyI) 2 0.143 false false false Author 10038794 /api/author/10038794 Fülöp Péter (Belgyógyászat, endokrinológia, lipidanyagcsere, elhízás) Fülöp Péter true 10038794 true Fülöp Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 117986503 /api/authorship/117986503 Lőrincz, Hajnalka [Lőrincz, Hajnalka (Egészségtudományok), szerző] Anyagcsere Betegségek Nem Önálló Tanszék (DE / ÁOK / BelgyI) 3 0.143 false false false Author 10037740 /api/author/10037740 Lőrincz Hajnalka (Egészségtudományok) Lőrincz Hajnalka true 10037740 true Lőrincz Hajnalka true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 117986504 /api/authorship/117986504 Dani, Győző 4 0.14285715 false false false Dani Győző true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 117986505 /api/authorship/117986505 Tajtiné, Krisztina Fazekas 5 0.14285715 false false false Tajtiné Krisztina Fazekas true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 117986506 /api/authorship/117986506 Thury, Attila 6 0.14285715 false false false Thury Attila true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 117986507 /api/authorship/117986507 Paragh, György ✉ [Paragh, György (Belgyógyászat), szerző] Anyagcsere Betegségek Nem Önálló Tanszék (DE / ÁOK / BelgyI) 7 0.143 false true true Author 10003445 /api/author/10003445 Paragh György (Belgyógyászat) Paragh György true 10003445 true Paragh György true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 26700617 /api/publicationidentifier/26700617 DOI: 10.3390/jcm13123398 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/jcm13123398 https://doi.org/10.3390/jcm13123398 false true PublicationIdentifier 26866561 /api/publicationidentifier/26866561 WoS: 001256023400001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001256023400001 https://www.webofscience.com/wos/woscc/full-record/001256023400001 false true PublicationIdentifier 26866560 /api/publicationidentifier/26866560 Scopus: 85197174794 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85197174794 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85197174794 false true PublicationIdentifier 29594642 /api/publicationidentifier/29594642 PubMed: 38929927 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38929927 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38929927&dopt=Abstract false true PublicationIdentifier 26700618 /api/publicationidentifier/26700618 Egyéb URL: https://www.mdpi.com/2077-0383/13/12/3398 PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true https://www.mdpi.com/2077-0383/13/12/3398 https://www.mdpi.com/2077-0383/13/12/3398 false true SjrRating 11482758 /api/sjrrating/11482758 sjr:Q1 (2024) Scopus - Medicine (miscellaneous) JOURNAL OF CLINICAL MEDICINE 2077-0383 607 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2701 /api/classificationexternal/2701 Scopus - Medicine (miscellaneous) true 2701 true Q1 DIRECT true true Reference 55045617 /api/reference/55045617 1. Baigent 2010: Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials., Lancet, 376, p. 1670, DOI: 10.1016/S0140-6736(10)61350-5 1 10.1016/S0140-6736(10)61350-5 false true Reference 55045618 /api/reference/55045618 2. Cannon 2015: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes., N. Engl. J. Med., 372, p. 2387, DOI: 10.1056/NEJMoa1410489 2 10.1056/NEJMoa1410489 false true Reference 55045619 /api/reference/55045619 3. Giugliano 2017: Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial., JAMA Cardiol., 2, p. 547, DOI: 10.1001/jamacardio.2017.0083 3 10.1001/jamacardio.2017.0083 false true Reference 55045620 /api/reference/55045620 4. Sabatine 2017: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease., N. Engl. J. Med., 376, p. 1713, DOI: 10.1056/NEJMoa1615664 4 10.1056/NEJMoa1615664 false true Reference 55045621 /api/reference/55045621 5. Schwartz 2018: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome., N. Engl. J. Med., 379, p. 2097, DOI: 10.1056/NEJMoa1801174 5 10.1056/NEJMoa1801174 false true Reference 55045622 /api/reference/55045622 6. Nissen 2004: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial., JAMA, 291, p. 1071, DOI: 10.1001/jama.291.9.1071 6 10.1001/jama.291.9.1071 false true Reference 55045623 /api/reference/55045623 7. Nissen 2006: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial., JAMA, 295, p. 1556, DOI: 10.1001/jama.295.13.jpc60002 7 10.1001/jama.295.13.jpc60002 false true Reference 55045624 /api/reference/55045624 8. Mach 2020: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk., Eur. Heart J., 41, p. 111, DOI: 10.1093/eurheartj/ehz455 8 10.1093/eurheartj/ehz455 false true Reference 55045625 /api/reference/55045625 9. Ray 2021: EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI study., Eur. J. Prev. Cardiol., 28, p. 1279, DOI: 10.1093/eurjpc/zwaa047 9 10.1093/eurjpc/zwaa047 false true Reference 55045626 /api/reference/55045626 10. Vrablik 2021: Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study., Atherosclerosis, 334, p. 66, DOI: 10.1016/j.atherosclerosis.2021.08.035 10 10.1016/j.atherosclerosis.2021.08.035 false true Reference 55045627 /api/reference/55045627 11. Mark 2020: Recommendations of statin treatment after acute coronary syndrome: Hungarian experiences., Atherosclerosis, 303, p. 53, DOI: 10.1016/j.atherosclerosis.2020.03.025 11 10.1016/j.atherosclerosis.2020.03.025 false true Reference 55045628 /api/reference/55045628 12. Nagy 2018: Lipid-lowering therapy of patients suffering from acute coronary syndrome in a Hungarian county hospital in 2015., Orv. Hetil., 159, p. 478 12 false true Reference 55045629 /api/reference/55045629 13. Dani 2020: Lipid lowering therapy of patients after intervention due to acute coronary syndrome and a recommendation for further controls., Cardiol. Hung., 50, p. 29 13 false true Reference 55045630 /api/reference/55045630 14. Zhang 2020: In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19., Cell Metab., 32, p. 176, DOI: 10.1016/j.cmet.2020.06.015 14 10.1016/j.cmet.2020.06.015 false true Reference 55045631 /api/reference/55045631 15. Kow 2020: Meta-analysis of Effect of Statins in Patients with COVID-19., Am. J. Cardiol., 134, p. 153, DOI: 10.1016/j.amjcard.2020.08.004 15 10.1016/j.amjcard.2020.08.004 false true Reference 55045632 /api/reference/55045632 16. Gupta 2021: Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19., Nat. Commun., 12, p. 1325, DOI: 10.1038/s41467-021-21553-1 16 10.1038/s41467-021-21553-1 false true Reference 55045633 /api/reference/55045633 17. Huang 2021: Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study., eLife, 10, p. e73873, DOI: 10.7554/eLife.73873 17 10.7554/eLife.73873 false true Reference 55045634 /api/reference/55045634 18. Ridker 2023: Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials., Lancet, 401, p. 1293, DOI: 10.1016/S0140-6736(23)00215-5 18 10.1016/S0140-6736(23)00215-5 false true Reference 55045635 /api/reference/55045635 19. Verdoia 2018: Impact of statin therapy on the immature platelet count in patients with coronary artery disease: A single centre cohort study., Int. J. Cardiol., 272, p. 40, DOI: 10.1016/j.ijcard.2018.08.039 19 10.1016/j.ijcard.2018.08.039 false true Reference 55045636 /api/reference/55045636 20. Sikora 2013: Effect of statins on platelet function in patients with hyperlipidemia., Arch. Med. Sci., 9, p. 622, DOI: 10.5114/aoms.2013.36905 20 10.5114/aoms.2013.36905 false true Reference 55045637 /api/reference/55045637 21. Bromage 2021: The collateral cardiovascular damage of COVID-19: Only history will reveal the depth of the iceberg., Eur. Heart J., 42, p. 1524, DOI: 10.1093/eurheartj/ehab097 21 10.1093/eurheartj/ehab097 false true Reference 55045638 /api/reference/55045638 22. Voith 2023: Coronary intervention in myocardial infarction during SARS-COVID-19 pandemic., Cardiol. Hung., 53, p. 37, DOI: 10.26430/CHUNGARICA.2023.53.1.37 22 10.26430/CHUNGARICA.2023.53.1.37 false true Reference 55045639 /api/reference/55045639 23. Friedewald 1972: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge., Clin. Chem., 18, p. 499, DOI: 10.1093/clinchem/18.6.499 23 10.1093/clinchem/18.6.499 false true Reference 55045640 /api/reference/55045640 24. Martin 2013: Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications., J. Am. Coll. Cardiol., 62, p. 732, DOI: 10.1016/j.jacc.2013.01.079 24 10.1016/j.jacc.2013.01.079 false true Reference 55045641 /api/reference/55045641 25. Martin 2018: Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights from the FOURIER Trial., JAMA Cardiol., 3, p. 749, DOI: 10.1001/jamacardio.2018.1533 25 10.1001/jamacardio.2018.1533 false true Reference 55045642 /api/reference/55045642 26. Byrne 2023: 2023 ESC Guidelines for the management of acute coronary syndromes., Eur. Heart J., 44, p. 3720, DOI: 10.1093/eurheartj/ehad191 26 10.1093/eurheartj/ehad191 false true Reference 55045643 /api/reference/55045643 27. Reiber 2022: Comparison of low-density lipoprotein cholesterol level calculated using the modified Martin/Hopkins estimation or the Friedewald formula with direct homogeneous assay measured low-density lipoprotein cholesterol., Arch. Med. Sci., 18, p. 577 27 false true Reference 55045644 /api/reference/55045644 28. Banach 2021: Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)., Pharmacol. Res., 166, p. 105499, DOI: 10.1016/j.phrs.2021.105499 28 10.1016/j.phrs.2021.105499 false true Reference 55045645 /api/reference/55045645 29. (2023, January 01). SWEDEHEART. Annual Report. Available online: https://www.ucr.uu.se/swedeheart/dokument-sh/arsrapporter-sh/01-swedeheart-annual-report-2022-english/viewdocument/3479. 29 false true Reference 55045646 /api/reference/55045646 30. Schubert 2021: Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: A Swedish nationwide cohort study., Eur. Heart J., 42, p. 243, DOI: 10.1093/eurheartj/ehaa1011 30 10.1093/eurheartj/ehaa1011 false true Reference 55045647 /api/reference/55045647 31. Klimis 2019: Clinical consequences of poor adherence to lipid-lowering therapy in patients with cardiovascular disease: Can we do better?., Heart Asia, 11, p. e011200, DOI: 10.1136/heartasia-2019-011200 31 10.1136/heartasia-2019-011200 false true Reference 55045648 /api/reference/55045648 32. Schiele 2021: Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients., Int. J. Cardiol., 332, p. 22, DOI: 10.1016/j.ijcard.2021.03.007 32 10.1016/j.ijcard.2021.03.007 false true Reference 55045649 /api/reference/55045649 33. Voith 2021: Primary coronary intervention in ST-elevation myocardial infarction., Orvosi Hetil., 162, p. 497, DOI: 10.1556/650.2021.31907 33 10.1556/650.2021.31907 false true Reference 55045650 /api/reference/55045650 34. Mansoor 2023: Upfront Combination of Statin and Ezetimibe for Patients with Acute Coronary Syndrome: Time for a New Approach?., J. Am. Heart Assoc., 12, p. e031615, DOI: 10.1161/JAHA.123.031615 34 10.1161/JAHA.123.031615 false true Reference 55045651 /api/reference/55045651 35. Dintshi, M., Kone, N., and Khoza, S. (2022). Comparison of measured LDL cholesterol with calculated LDL-cholesterol using the Friedewald and Martin-Hopkins formulae in diabetic adults at Charlotte Maxeke Johannesburg Academic Hospital/NHLS Laboratory. PLoS ONE, 17., DOI: 10.1371/journal.pone.0277981 35 10.1371/journal.pone.0277981 false true Reference 55045652 /api/reference/55045652 36. Mehta 2018: Performance of LDL-C calculated with Martin’s formula compared to the Friedewald equation in familial combined hyperlipidemia., Atherosclerosis, 277, p. 204, DOI: 10.1016/j.atherosclerosis.2018.06.868 36 10.1016/j.atherosclerosis.2018.06.868 false true Reference 55045653 /api/reference/55045653 37. Ray 2022: Combination lipid-lowering therapy as first-line strategy in very high-risk patients., Eur. Heart J., 43, p. 830, DOI: 10.1093/eurheartj/ehab718 37 10.1093/eurheartj/ehab718 false true Reference 55045654 /api/reference/55045654 38. Mark 2012: The Effect of Switching to the High-Efficient Rosuvastatin on the Success of Lipid Lowering Therapy in High Risk Patients., CORVUS (Control Targets High Vasc. Risk Patients Using Eff. Statins) Study, 4, p. 2 38 false true Reference 55045655 /api/reference/55045655 39. Jankowski 2019: Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries., Atherosclerosis, 285, p. 135, DOI: 10.1016/j.atherosclerosis.2019.03.014 39 10.1016/j.atherosclerosis.2019.03.014 false true Reference 55045656 /api/reference/55045656 40. Edfors 2022: Differences in characteristics, treatments and outcomes in patients with non-ST-elevation myocardial infarction: Novel insights from four national European continuous real-world registries., Eur. Heart J. Qual. Care Clin. Outcomes, 8, p. 429, DOI: 10.1093/ehjqcco/qcab013 40 10.1093/ehjqcco/qcab013 false true Reference 55045657 /api/reference/55045657 41. Ainla 2022: Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway, and Sweden according to national ongoing registries., Eur. Heart J. Qual. Care Clin. Outcomes, 8, p. 307, DOI: 10.1093/ehjqcco/qcaa098 41 10.1093/ehjqcco/qcaa098 false true Reference 55045658 /api/reference/55045658 42. Ekblom 2022: Participation in exercise-based cardiac rehabilitation is related to reduced total mortality in both men and women: Results from the SWEDEHEART registry., Eur. J. Prev. Cardiol., 29, p. 485, DOI: 10.1093/eurjpc/zwab083 42 10.1093/eurjpc/zwab083 false true /api/publication/35061032 Mark Laszlo et al. The Evaluation of Lipid-Lowering Treatment in Patients with Acute Coronary Syndrome in a Hungarian Invasive Centre in 2015, 2017, and during the COVID-19 Pandemic—The Comparison of the Achieved LDL-Cholesterol Values Calculated with Friedewald and Martin–Hopkins Methods. (2024) JOURNAL OF CLINICAL MEDICINE 2077-0383 13 12 p. 3398<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10047613"><a href="/gui2/?type=authors&mode=browse&sel=10047613" target="_blank">Mark Laszlo (<span class="authorship-author-name">Márk László</span> <span class="authorAux-mtmt"> Belgyógyászat, kardiológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10038794"><a href="/gui2/?type=authors&mode=browse&sel=10038794" target="_blank">Fülöp Péter (<span class="authorship-author-name">Fülöp Péter</span> <span class="authorAux-mtmt"> Belgyógyászat, endokrinológia, lipidanyagcsere,...</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/<span title="Belgyógyászati Intézet">BelgyI</span>/Anyagcsere Betegségek Nem Önálló Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10037740"><a href="/gui2/?type=authors&mode=browse&sel=10037740" target="_blank">Lőrincz Hajnalka (<span class="authorship-author-name">Lőrincz Hajnalka</span> <span class="authorAux-mtmt"> Egészségtudományok</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/<span title="Belgyógyászati Intézet">BelgyI</span>/Anyagcsere Betegségek Nem Önálló Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Dani Győző </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Tajtiné Krisztina Fazekas </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Thury Attila </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10003445"><a href="/gui2/?type=authors&mode=browse&sel=10003445" target="_blank">Paragh György ✉ (<span class="authorship-author-name">Paragh György</span> <span class="authorAux-mtmt"> Belgyógyászat</span>) </a> </span> <span class="author-affil"><span title="Debreceni Egyetem">DE</span>/<span title="Általános Orvostudományi Kar">ÁOK</span>/<span title="Belgyógyászati Intézet">BelgyI</span>/Anyagcsere Betegségek Nem Önálló Tanszék</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;35061032" target="_blank">The Evaluation of Lipid-Lowering Treatment in Patients with Acute Coronary Syndrome in a Hungarian Invasive Centre in 2015, 2017, and during the COVID-19 Pandemic—The Comparison of the Achieved LDL-Cholesterol Values Calculated with Friedewald and Martin–Hopkins Methods</a></div> <div> <span class="journal-title">JOURNAL OF CLINICAL MEDICINE</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2077-0383">2077-0383</a>)</span>: <span class="journal-volume">13</span> <span class="journal-issue">12</span> <span class="page"> p. 3398. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/jcm13123398" target="_blank" href="https://doi.org/10.3390/jcm13123398"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001256023400001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001256023400001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85197174794" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85197174794"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="38929927" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38929927&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:black" title="https://www.mdpi.com/2077-0383/13/12/3398" target="_blank" href="https://www.mdpi.com/2077-0383/13/12/3398"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 2</span> | Független: 0 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 2 | Scopus jelölt:&nbsp;2 | WoS/Scopus jelölt:&nbsp;2 | DOI jelölt:&nbsp;2 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;35061032&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 13 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 35061032</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="lastModified">Utolsó módosítás: 2025.01.05. 22:11 Márk László (Belgyógyászat, kardiológia) </div> </div></div>